Penn Medicine's UK expansion reflects its pioneering approach, says Robert Vonderheide

Philadelphia-based Penn Medicine is not only one of the world’s leading research bodies, it is also a symbol of the global relevance of one of the USA’s proudest academic institutions to healthcare and scientific progress.

As home of the country’s oldest medical school and a pioneer of many medical firsts, Penn is at the forefront of research and clinical investigations across a number of treatment areas.

The center is especially seen as a leader in the development of new treatments in oncology, having played a key role in the development of Kymriah (tisagenlecleucel), the first CAR-T cancer therapy, led the research and clinical practice in the use of proton beam therapy and unearthed the first gene linked to cancer.